North America Dominates the Organ Preservation Industry

The organ preservation market was USD 243.7 million in 2022, and it will reach USD 442.6 million, propelling at a 7.7% compound annual growth rate by 2030.

To learn more about this report: https://bit.ly/47EJtZz

Organ preservation industry growth is significantly influenced by the rising incidence of multiple organ failure. Multi-organ failure occurs when many key organs in the body are unable to operate properly, frequently as a result of serious illnesses or major accidents. 

To give patients with multi-organ failure a chance at survival and better quality of life, organ transplantation becomes a significant therapy option.

A key factor in the growth of the organ preservation market is the rise in organ transplants and organ donors. Technology advancements in organ preservation are crucial in assisting the growing number of organ transplants. Before transplantation and during transit, these technologies guarantee that donated organs are healthy and functional.

North America held the largest industry share of 45% in 2022, and it is expected to show significant growth by 2030.

The healthcare system in North America is well-established and sophisticated, with cutting-edge hospitals, research institutes, and transplant centers. This area's supremacy in the industry is a result of the efficient organ preservation, transplantation, and post-transplant care made possible by the region's strong healthcare system. 

End-stage organ failure, including kidney, liver, heart, and lung failure, is extremely common in the region.  As a result, there is a significant need for organ transplantation and technologies for organ preservation are essential in satisfying this need.

The growth of the global organ preservation industry is mainly driven by the increasing elderly population and rising incidence of multiple organ failure, necessitating organ transplantation as a significant therapy option.

Read More

Amniotic Products Industry Is Led by North America

The amniotic products market was USD 810.4 million in 2022, and it will advance at an 8.7% compound annual growth rate, to touch USD 1,451.2 million, by 2030.

To learn more about this report: https://bit.ly/3P8MUQF

The growth of the industry is ascribed to the continuing research to enlarge the application area, utilization of these products for the treatment of eye and skin illnesses, and increasing prevalence of traumatic wounds and injuries because of burns, as well as the rising consciousness about the usage of amniotic products for their treatment.

In 2022, the membranes category, based on type, accounted for the largest share of the industry, of 80%. This is credited to the superior effectiveness of membranes over suspensions. Moreover, the category will advance at an exponential rate because of the increasing utilization of such membranes for various ophthalmic problems.

In 2022, the North American amniotic products industry was the largest contributor, with a 60% share. This is primarily attributed to the existence of well-established healthcare facilities and key industry players. Moreover, the surging focus being given to alternative technologies will further boost the growth of the regional industry.

APAC is likely to witness the fastest growth, with a 9% compound annual growth rate, in the years to come. This can be attributed to the rising disposable income and the economic growth across the nations of the region.

Moreover, several global companies are making notable findings in this area. Large unmet requirements and rising infrastructure of healthcare, mainly in India and Japan, will further boost the growth of the regional industry.

It is because of the increasing prevalence of traumatic wounds and injuries because of burns and the surging treatment for skin and eye disorders, the amniotic products industry will continue to advance in the years to come.

Read More

Biomarkers Industry Is Dominated by North America

The biomarkers industry was USD 54.5 billion in 2022, and it will reach USD 132.8 billion, advancing at a 11.8% CAGR, by 2030.

To learn more about this report: https://bit.ly/3OKAPQo

The growth in the industry is attributed to the surging incidence of chronic illnesses and advancements in the technologies utilized in the production of biomarkers and biomarker-based diagnostic tests, including biomarker signatures, which are enabling neurological illnesses more treatable.

In 2022, the consumables category, based on product type, held the largest share of the industry, of 70%. This is because of the increasing requirement for kit-based products for biomarker testing and the regular buying of consumables.

The software category is expected to witness the fastest growth in the years to come. This is because of the speedy acceptance of software-based methods in diagnostic labs for early and accurate disease diagnosis. Software-based biomarkers are particularly utilized in drug discovery, pharmacodynamic evaluation, and gene sequencing.

In 2022, North America held the largest share in the industry, of approximately 40%, and it will further advance at a robust rate throughout this decade. This is because of the increasing utilization of such markers in personalized drugs and numerous business development strategies implemented by the players, including collaborations and partnerships with major pharmaceutical and biotechnological businesses in this continent.

APAC will observe the fastest growth in the years to come. The surging incidence of cardiovascular and cancer illnesses has resulted in the increasing requirement for such agents in the continent for their detection.

With the increasing incidence of chronic illnesses and advancements in technologies, the demand for biomarkers will continue to increase in the years to come.

Read More

Cellular Health Screening Industry IS Led by North America

The cellular health screening market will power at a rate of 9.7% by the end of this decade, to reach USD 5,512.8 million by 2030.

To learn more about this report: https://bit.ly/3soV7Yj

This has a lot to do with the growing use of cellular health screening in personalized medicine, detecting ailments early, supporting in preventive care, and identification of diverse health problems; the growing count of awareness campaigns; the increasing acceptance of telomere performance programs; and the growing prevalence of chronic ailments mainly cancer globally.

The single-test panel category held a major share of the industry. This is because of its labor efficiency, affordability, and increased possibility for automation. Amongst single-panel tests, the requirement for telomere single-panel tests is will grow at the highest rate by the end of this decade. This is due to the fact that these offer precise info, aid in measurement of the length of telomere, and help in the determination of the age of cell.

North America led the cellular health screening market, and this trend will continue by the end of this decade, with USD 2.5 billion. This is because of the growing government funding for preventive healthcare, the increasing acceptance of novel technologies, the mounting consciousness about personalized medicine, and the expanding incidence of infectious and chronic diseases. 

The U.S. is the leading the industry in North America, and it will grow at a rate of 10% by the end of this decade. This because of the robust healthcare infra and the existence of a numerous key players. 

Europe is growing at a considerable rate. This is because of the growing elderly population, the growing incidences of chronic ailments, and the surging acceptance of cutting-edge screening methods for effective treatment of various diseases.

Due to the increasing focus toward a healthy life expectancy, the demand for cellular health screening solution will continue to grow.

Read More

North America Is Dominating Heart Pump Devices Market

The total value of the global heart pump devices market was USD 2,212.5 million in 2022, and it will rise at a growth rate of above 22.1% during 2023–2030, reaching USD 10,912.6 million by 2030. This can be credited to the increasing cardiovascular illness occurrence, growing elderly populace, and numerous new product introductions by industry players.

To learn more about this report: https://bit.ly/45kg0Ci

Worldwide, heart failure is one of the most common issues. It is an intricate clinical disorder characterized by the irregular working of the heart, which leads to unsatisfactory cardiac output. As per the Global Burden of Heart Failure article published by the NCBI in 2023, over 65 million individuals are impacted by this condition globally. An artificial heart pump can temporarily aid in the pumping action of the heart.

On the basis of product, ventricular assist devices cornered the largest share, of approximately 70%, in 2022. This is mainly because of the growing rate of technical improvements in such items by industry players and the unattainability of organ donors. The vital drivers for the category are the increasing patient pool going through heart failure and the long waiting list for operations.

In 2022, North America held the largest revenue share in the industry, of approximately 45%. This can be credited to the increasing demand for technically progressive cardiac support devices because of the growing occurrence of cardiovascular illnesses. As per government statistics, In Canada, heart illness is the second-leading reason for demise after cancer, with around 67,400 persons in the nation dying as a result of such problems in 2020.

Hence, the increasing cardiovascular illness occurrence, growing elderly populace, and numerous new product introductions by industry players are the major factors propelling the market.

Read More

Implantable Loop Recorders Industry To Reach USD 2,490.4 Million by 2030

The implantable loop recorders market will rise at a rate of 8% by the end of this decade, to reach USD 2,490.4 million by 2030. This is because of the growing incidence of heart diseases, the rising aging populace across all regions, the growing spending on healthcare, the developing new fields of clinical research, and the growing support of the governments for creating better healthcare infra.

To learn more about this report: https://bit.ly/3YIvrSy

Moreover, the rising variations in lifestyle, lack of healthy diet, and increasing fascination toward the consumption of junk food are the major reasons for the growing cases of chronic health conditions in older and younger populations. 

Also, these harsh health habits are the main reasons for the increasing incidences of CVDs and other chronic disorders. Furthermore, the increasing mortality occurrences of people suffering from chronic cardiac ailments have brought about the increasing acceptance of ILRs for better info and treatment of present heart patients.

The distribution of ILRs is conquered by the direct purchase of cardiac rhythm monitoring devices by ambulatory surgery centers, hospitals, cardiac centers, and others.

Also, Europe will grow considerably in the future. This is because of the existence of established healthcare infra and considerable healthcare investment. For example, Germany, France, the U.K., and Switzerland have an established healthcare industry, as a result of which new tech and diagnostic processes are used more frequently. Additionally, the fast surge in the aging population and the increasing CVD cases are generating a lucrative requirement for ILRs.

It is because of the increasing number of deaths happening as a result of CVDs all over the world, the demand for implantable loop recorders will continue to increase in the future.

Read More

Neoantigen Cancer Vaccine Industry to Observe Fastest Growth in Asia-Pacific

The global neoantigen cancer vaccine market was valued at USD 24.4 million in 2022, and it will advance at a mammoth 67.6% compound annual growth rate, to touch USD 1,322.8 million, by 2030.

To learn more about this report: https://bit.ly/47EUjP7

The key factor boosting the advancement of the industry include the mounting incidence of cancer and surging research activities all over the world. Moreover, because of the growing importance of personalized treatments of cancer, pharmaceutical companies are focusing on R&D to meet the existing and possible requirements for neoantigen cancer vaccines.

Based on product type, the personalized category accounted for the largest share, of 70%, in 2022. Developing personalized cancer vaccines need suitable antigen screening in specific patients. The exceptional potential of personalized neoantigens to induce long-lasting tumor-specific memory T-cell populations has resulted in the mounting utilization of such drugs for effective cancer treatment, therefore boosting the advancement of this category.

In 2022, the nucleic acid category, based on type, accounted for the largest neoantigen cancer vaccine market share, of 55%. This can be attributed to the increasing number of drug manufacturers actively involved in producing advanced and effective nucleic acid-based vaccines.

The APAC neoantigen cancer vaccine industry will witness the fastest growth in the coming years. This is primarily credited to the speedy upgradation in targeted immunotherapy, as a result of the surging number of research initiatives in the regional nations, mainly due to the increasing cases of cancer.

With the surging research activities, as well as the increasing prevalence of cancer all over the world, the neoantigen cancer vaccine industry will continue to advance in the years to come.

Read More